Orion Biotech Opportunities - Warrants (15/04/2025) EBIT

Orion Biotech Opportunities - Warrants (15/04/2025) posts a EBIT of $-900K as of December 2022. That compares with $-630K in the prior-year period — down 43.2% year over year. That is above the sector sector average of $-6.4M. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, Orion Biotech Opportunities - Warrants (15/04/2025)'s EBIT was $-630K. The latest reading is $-900K — a 43.2% year-over-year decrease (period ending December 2022). Use the history and growth charts on this page for a longer lookback.

For its sector stocks, a EBIT near $-6.4M is typical. Orion Biotech Opportunities - Warrants (15/04/2025)'s $-900K is higher that level. That is roughly 85.9% above the sector mean. Whether that is a warning or an opportunity depends on growth outlook and other fundamentals shown elsewhere on Stockcircle.

EBIT is one piece of Orion Biotech Opportunities - Warrants (15/04/2025)'s financial statement story. At $-900K, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for ORIAW's EBIT usually means three checks: (1) trend versus prior periods, (2) level versus peers (average $-6.4M), and (3) consistency with growth and profitability. This page covers the first two; Orion Biotech Opportunities - Warrants (15/04/2025)'s other metric pages and overview cover the third.